Provided by Tiger Trade Technology Pte. Ltd.

Intellia Therapeutics

13.13
-0.1400-1.06%
Post-market: 13.06-0.0700-0.53%19:55 EDT
Volume:2.75M
Turnover:35.62M
Market Cap:1.55B
PE:-3.45
High:13.27
Open:12.69
Low:12.47
Close:13.27
52wk High:28.25
52wk Low:5.90
Shares:118.13M
Float Shares:112.00M
Volume Ratio:0.68
T/O Rate:2.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8100
EPS(LYR):-3.8100
ROE:-53.48%
ROA:-27.11%
PB:2.31
PE(LYR):-3.45

Loading ...

Synopsys, Reddit, Intellia, Symbotic, Seagate Insider Shock

TIPRANKS
·
Jan 10

Intellia Therapeutics VP and Chief Accounting Officer Michael P. Dube Reports Disposal of Common Shares

Reuters
·
Jan 08

BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating

MT Newswires Live
·
Jan 06

Intellia Therapeutics Awards Inducement Grants to New Employees

Reuters
·
Jan 03

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jan 03

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

Intellia Therapeutics CEO John M. Leonard Reports Disposal of Common Shares

Reuters
·
Dec 13, 2025

Why Intellia Therapeutics (NTLA) Is Up 6.9% After Disclosing Serious Liver Safety Events In Lead CRISPR Trials

Simply Wall St.
·
Dec 08, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 06, 2025

Intellia Therapeutics Q3 Net Income USD -101.324 Million

Reuters
·
Nov 20, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV)

TIPRANKS
·
Nov 16, 2025

Stock Track | Intellia Therapeutics Plummets 5.01% Following Wolfe Research Downgrade on Nexig Safety Concerns

Stock Track
·
Nov 13, 2025

Stock Track | Intellia Therapeutics Plummets 5% Following Wolfe Research Downgrade Over Nex-z Safety Concerns

Stock Track
·
Nov 13, 2025

Wall Street Top Analysts' Latest Ratings: AT&T Upgraded

Deep News
·
Nov 12, 2025

Wolfe downgrades Intellia to Peer Perform on Nex-z safety issue

TIPRANKS
·
Nov 12, 2025

Stock Track | Intellia Therapeutics Surges 5.04% Despite Multiple Analyst Downgrades

Stock Track
·
Nov 12, 2025

Stock Track | Intellia Therapeutics Surges 5% Despite Analyst Downgrades, Defying Market Expectations

Stock Track
·
Nov 12, 2025

Intellia Therapeutics Cut to Hold From Buy by Jones Trading

Dow Jones
·
Nov 12, 2025

Intellia Therapeutics downgraded to Hold from Buy at JonesResearch

TIPRANKS
·
Nov 11, 2025

JonesTrading downgrades Intellia Therapeutics (NTLA) to a Hold

TIPRANKS
·
Nov 11, 2025